CXCR4 and neoplasm: As compared to free oligo‐FdU, repeated T22‐GFP‐H6‐FdU administration, in cell line and patient‐derived CRC mouse models, blocks CXCR4+ tumor emboli intravasation in colonic peri‐tumoral vessels and completely prevents metastases development in a high percent of mice.